Annexon Biosciences

Annexon Biosciences is developing first-in-class C1q inhibitors to halt the classical complement pathway, a key driver of tissue damage in severe diseases of the body, brain, and eye. Founded on groundbreaking research from Stanford, the company has built a versatile platform with multiple drug candidates in late-stage clinical trials, including ANX005 for GBS and ANX007 for geographic atrophy. Its strategy focuses on achieving functional clinical benefits in areas of high unmet need, positioning it as a leader in upstream complement inhibition with significant near-term catalysts.

Platform focused on selective inhibition of C1q, the initiator of the classical complement pathway, using monoclonal antibodies and antigen-binding fragments (Fabs) delivered via intravenous, intravitreal, and subcutaneous routes to treat diseases across the body, brain, and eye.

Annexon's primary competition in GA comes from approved C3 (Apellis) and C5 (Astellas/Iveric) inhibitors. Its C1q-focused, upstream inhibition strategy is a key differentiator, potentially offering a more comprehensive blockade of the classical pathway implicated in neural and ocular damage. In GBS, it faces standard-of-care therapies but has no direct targeted biologic competitors.